Evidence map›Paper›PMID 31861366›Full record

ArticleMetabolites2019

Electromembrane Extraction of Highly Polar Compounds: Analysis of Cardiovascular Biomarkers in Plasma.

Nicolas Drouin, Tim Kloots, Julie Schappler, Serge Rudaz, Isabelle Kohler, Amy Harms, Petrus Wilhelmus Lindenburg, Thomas Hankemeier

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Nicolas DrouinInstitute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University Medical Centre, 1206 Geneva, Switzerland.
Tim KlootsDivision of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Julie SchapplerInstitute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University Medical Centre, 1206 Geneva, Switzerland.
Serge RudazInstitute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University Medical Centre, 1206 Geneva, Switzerland.
Isabelle KohlerDivision of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Amy HarmsDivision of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Petrus Wilhelmus LindenburgDivision of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Thomas HankemeierDivision of Systems Biomedicine and Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
Leiden University · NLHES-SO University of Applied Sciences and Arts Western Switzerland · CH

Funding

Horizon 2020 Marie Sklodowska-Curie CO-FUND 707404Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung P1GEP3_174791
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) represent a major concern in today's society, with more than 17.5 million deaths reported annually worldwide. Recently, five metabolites related to the gut metabolism of phospholipids were identified as promising predictive biomarker candidates for CVD. Validation of those biomarker candidates is crucial for applications to the clinic, showing the need for high-throughput analysis of large numbers of samples. These five compounds, trimethylamine N-oxide (TMAO), choline, betaine, l-carnitine, and deoxy-l-carnitine (4-trimethylammoniobutanoic acid), are highly polar compounds and show poor retention on conventional reversed phase chromatography, which can lead to strong matrix effects when using mass spectrometry detection, especially when high-throughput analysis approaches are used with limited separation of analytes from interferences. In order to reduce the potential matrix effects, we propose a novel fast parallel electromembrane extraction (Pa-EME) method for the analysis of these metabolites in plasma samples. The evaluation of Pa-EME parameters was performed using multi segment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS). Recoveries up to 100% were achieved, with variability as low as 2%. Overall, this study highlights the necessity of protein precipitation prior to EME for the extraction of highly polar compounds. The developed Pa-EME method was evaluated in terms of concentration range and response function, as well as matrix effects using fast-LC-MS/MS. Finally, the developed workflow was compared to conventional sample pre-treatment, i.e., protein precipitation using methanol, and fast-LC-MS/MS. Data show very strong correlations between both workflows, highlighting the great potential of Pa-EME for high-throughput biological applications.

Indexed as

capillary electrophoresis–mass spectrometrycardiovascular diseaseelectromembrane extractionliquid chromatography–mass spectrometrymulti-segment injection

Identifiers

PMID31861366
PMCPMC7022788
OpenAlexW2994766233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.